Bullish indicating open at $55-$60, IPO prices at $37
On Monday, Jefferies analyst Roger Song confirmed a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a steady price target of $46.00. Song’s analysis highlighted TG Therapeutics’ financial status as of March 31, 2025, noting the company’s cash and equivalents totaling $276.2 million. The company’s research and development (R&D) expenses were approximately $46.4 million, which included around $20 million for subcutaneous material costs, and selling, general, and administrative (SG&A) expenses were about $50.3 million for the first quarter of 2025.
TG Therapeutics has reassured stakeholders of its financial strategy, aiming to maintain total non-GAAP operating expenses, excluding the cost of goods sold (COGS), at roughly $300 million for the year 2025. The company has consumed all pre-commercial inventory, which is reflected in the COGS. With revenue growth of 40.8% over the last twelve months and total revenue reaching $329 million, TG Therapeutics anticipates maintaining a cash-neutral position throughout the year.
The company has indicated that while immediate earnings per share (EPS) are not the primary focus, there is confidence in achieving profitability due to continued strong revenue growth. InvestingPro analysis shows analysts expect EPS to reach $1.06 in 2025, supporting the company’s positive outlook. According to Song, TG Therapeutics is positioned well financially and operationally, with a clear path to maintain stability and pursue growth opportunities. InvestingPro subscribers can access 15+ additional key insights and detailed financial metrics in the comprehensive Pro Research Report.
Investors are expected to monitor TG Therapeutics’ progress closely, as the company navigates its operational and financial goals. The endorsement from Jefferies, with a reiterated Buy rating and a $46.00 price target, suggests confidence in the company’s strategy and potential for future success. The company currently has a market capitalization of $6.04 billion and maintains an overall "GREAT" financial health score according to InvestingPro metrics.
In other recent news, TG Therapeutics Inc . reported its first-quarter 2025 earnings, revealing a significant miss on earnings per share (EPS) but a slight beat on revenue expectations. The company’s EPS was $0.03, falling short of the forecasted $0.16, while revenue reached $119.7 million, surpassing the $117.13 million estimate. This revenue figure represents a 137% year-over-year growth, which is noteworthy despite the EPS miss. TG Therapeutics has also raised its full-year 2025 U.S. net revenue guidance from $525 million to $560 million.
In addition to financial updates, the company is preparing for a direct-to-patient TV commercial campaign to boost awareness and adoption of its products. The company maintains a strong position in the anti-CD20 market, capturing approximately 25% of the intravenous segment. On the analyst front, there were no specific upgrades or downgrades mentioned in the recent reports. However, analysts from firms such as TD Cowen and Jefferies are closely monitoring the company’s competitive dynamics and product developments. These developments highlight the company’s ongoing efforts to expand its market share and enhance its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.